BioAffinity Technologies, Inc.'s Lock-Up Period To End on February 28th (NASDAQ:BIAF)
BioAffinity Technologies, Inc.'s Lock-Up Period To End on February 28th (NASDAQ:BIAF)
bioAffinity Technologies' (NASDAQ:BIAF – Get Rating) lock-up period will end on Tuesday, February 28th. bioAffinity Technologies had issued 1,282,600 shares in its IPO on September 1st. The total size of the offering was $7,862,338 based on an initial share price of $6.13. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
生物親和技術公司（NASDAQ：BIAF-獲得評級）鎖定期將於 2 月 28 日（週二）結束，生物親和科技已於 9 月 1 日在其首次公開發行中發行了 1,282,600 股。根據初始股價 6.13 美元計算，該次發行的總金額為 7,862,338 美元。公司內部人員和主要股東擁有的公司股份將在鎖定期結束後有資格進行交易。
bioAffinity Technologies Stock Down 7.2 %
生物親和技術庫存下跌 7.2%
Shares of BIAF opened at $2.06 on Tuesday. The company's fifty day moving average is $2.00. bioAffinity Technologies has a 1-year low of $1.31 and a 1-year high of $15.55.
BIAF 的股票在周二開盤 2.06 美元。該公司的五十天移動平均線為 2.00 美元，生物聯合科技的 1 年低點為 1.31 美元和 1 年高點 15.55 美元。
Institutional Trading of bioAffinity Technologies
生物親和技術的機構交易
An institutional investor recently bought a new position in bioAffinity Technologies stock. Jane Street Group LLC bought a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Rating) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,004 shares of the company's stock, valued at approximately $32,000. Jane Street Group LLC owned 0.40% of bioAffinity Technologies as of its most recent filing with the SEC. 2.43% of the stock is owned by hedge funds and other institutional investors.
一名機構投資者最近購買了生物親和科技股票的新倉位。簡街集團有限責任公司買了生物親和技術公司的新位置, 公司. (NASDAQ: BIAF — 獲得評級) 在第三季度, 根據其最近與美國證券交易委員會的披露.該公司購買了該公司股票的 11,004 股，價值約為 32,000 美元。簡街集團有限責任公司擁有 0.40％ 的生物聯合技術，截至其最近在美國證券交易委員會提交申請。2.43％ 的股票由對沖基金和其他機構投資者擁有。
bioAffinity Technologies Company Profile
生物親和科技公司簡介
(Get Rating)
(取得評分)
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.
BioAffinity 科技有限公司是一家生物技術公司，致力於開發非侵入性診斷測試和靶向癌症治療。該公司提供 CypAth 肺部診斷 test，用於及早發現肺癌。它還研究標靶療法以治療細胞水平的癌症。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAF)
- Is Alibaba the Jet fuel Launching China into New Frontiers?
- Applied Materials Is In The Semiconductor Sweet Spot
- Can Coinbase Shake Off Regulatory Risk After Kraken's Shakedown?
- Tripadvisor Stock Gap and Crap. Here's Why.
- Could Copper be the Shiny Object That Lifts Barrick Gold?
- 獲取有關生物親和技術研究報告的免費副本
- 阿里巴巴是將中國推向新疆域的噴氣燃料嗎？
- 應用材料處於半導體的甜蜜點
- 可以 Coinbase 擺脫監管風險後海妖的震動?
- 貓途鷹股票差距和廢話。這就是為什麼。
- 銅可以是提升巴里克黃金的閃亮物體嗎？
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收生物親和技術的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 BioAffinity 技術和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。